Literature DB >> 31841197

MiR-92b inhibited cells EMT by targeting Gabra3 and predicted prognosis of triple negative breast cancer patients.

Y-Y Li1, X-H Zheng, A-P Deng, Y Wang, J Liu, Q Zhou, G-Y Cheng, Q Jiang.   

Abstract

OBJECTIVE: Triple negative breast cancer (TNBC) is a subtype of breast cancer without the three markers, which has a poor prognosis than other types. Recently, studies have identified that microRNA-92b (miR-92b) acted as potential oncogene in tumor progression, however, the biological roles of miR-92b in TNBC remain unknown. The purpose of this study was to investigate the functions of miR-92b and verify its effect on the regulation of Gabra3 in TNBC.
MATERIALS AND METHODS: Dual-Luciferase reporter assay was recruited to confirm whether miR-92b directly binds to the 3'-untranslated region (3'-UTR) of Gabra3 mRNA in TNBC. Transwell assay was employed to analyze the capacities of migration and invasion. Western blot was applied to evaluate the expression of the special proteins that including Gabra3, epithelial-mesenchymal transition (EMT) markers and GAPDH.
RESULTS: We demonstrated that miR-92b was remarkably low expressed in TNBC tissues and cell lines, and particularly in inhibiting the migration, invasion and EMT of TNBC cells. On the contrary, Gabra3 was significantly overexpressed in TNBC tissues and cell lines in comparison with the corresponding paracancerous tissues and the normal breast epithelial cell line. The expression of miR-92b had a negative correlation with the expression of Gabra3 in TNBC tissues. Downregulation of Gabra3 could inhibit the migration, invasion and EMT of TNBC cells. MiR-92b mediated the expression of Gabra3 through directly binding to the 3'-UTR of Gabra3 mRNA. In addition, low expression of miR-92b or overexpression of Gabra3 predicted poor prognosis of TNBC patients.
CONCLUSIONS: MiR-92b inhibited the migration and invasion-mediated EMT through directly targeting the 3'-UTR of Gabra3 mRNA in triple negative breast cancer. The newly identified miR-92b/Gabra3 axis may make it to be a new target for clinical diagnosis and treatment of TNBC.

Entities:  

Year:  2019        PMID: 31841197     DOI: 10.26355/eurrev_201912_19682

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  Association between microRNA-146a, -499a and -196a-2 SNPs and non-small cell lung cancer: a case-control study involving 2249 subjects.

Authors:  Hao Qiu; Zhiqiang Xie; Weifeng Tang; Chao Liu; Yafeng Wang; Haiyong Gu; Qingfeng Zheng
Journal:  Biosci Rep       Date:  2021-02-26       Impact factor: 3.840

Review 2.  The Impact of Non-coding RNAs in the Epithelial to Mesenchymal Transition.

Authors:  Bashdar Mahmud Hussen; Hamed Shoorei; Mahdi Mohaqiq; Marcel E Dinger; Hazha Jamal Hidayat; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  Front Mol Biosci       Date:  2021-03-26

3.  Expression levels and clinical values of miR-92b-3p in breast cancer.

Authors:  Yu Du; Zhuang Miao; Kedi Wang; Yan Lv; Lijuan Qiu; Lusheng Guo
Journal:  World J Surg Oncol       Date:  2021-08-11       Impact factor: 2.754

4.  Long non-coding RNA OIP5-AS1 suppresses microRNA-92a to augment proliferation and metastasis of ovarian cancer cells through upregulating ITGA6.

Authors:  Yujue Wang; Lingling Li; Xun Zhang; Xiaolan Zhao
Journal:  J Ovarian Res       Date:  2022-02-16       Impact factor: 4.234

5.  Specificity protein 1/microRNA-92b forms a feedback loop promoting the migration and invasion of head and neck squamous cell carcinoma.

Authors:  Pai Pang; Hui Fang; Hong Wu; Song Wang; Minda Liu; Shan Jin; Zhongzheng Qi; Zhenning Li; Fayu Liu; Changfu Sun
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

6.  MiR-92b-3p inhibits proliferation and migration of C2C12 cells.

Authors:  Zijian Ye; Jia Shi; Zuocheng Ning; Lianjie Hou; Ching Yuan Hu; Chong Wang
Journal:  Cell Cycle       Date:  2020-10-12       Impact factor: 4.534

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.